

**Reference Number:** FOI202223/004  
**From:** Private Individual  
**Date:** 01 April 2022  
**Subject:** Number of metastatic non-small cell lung cancer (NSCLC) patients treated with a list of specific drugs

- Q1 In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:
- a. Afatinib
  - b. Alectinib
  - c. Atezolizumab monotherapy
  - d. Atezolizumab in combination
  - e. Bevacizumab
  - f. Brigatinib
  - g. Capmatenib
  - h. Ceritinib
  - i. Crizotinib
  - j. Dacomitinib
  - k. Dabrafenib with Trametinib
  - l. Docetaxel monotherapy
  - m. Durvalumab
  - n. Erlotinib
  - o. Gefitinib
  - p. Gemcitabine
  - q. Nintedanib with Docetaxel
  - r. Nivolumab
  - s. Osimertinib
  - t. Paclitaxel
  - u. Pembrolizumab monotherapy
  - v. Pembrolizumab in combination
  - w. Pemetrexed with Carboplatin/Cisplatin
  - x. Tepotinib
  - y. Vinorelbine with Cisplatin/Carboplatin
  - z. Any other SACT
  - aa. Palliative care only

A1 a-z: Information not held – we do not use any of the drugs listed  
aa: Zero